IOncology

At the recent "Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association," Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier invited Prof. Wang for an exclusive interview to share insights on the key findings presented at the ASCO 2025 conference in the field of HER2-positive breast cancer and their clinical implications, along with perspectives on future research directions.

Editor’s Note: At the recent “Yangtze River Academic Breast Cancer Mid-Year Exchange Conference & CSOE Tumor Drug Clinical Research Committee Mid-Year Meeting & 2025 ASCO Debrief,” Professor Ting Li from…

Editor’s Note: The DESTINY-Breast09 (DB-09) study, recently presented at the ASCO Annual Meeting, has sparked widespread attention among oncology experts and is poised to reshape the first-line treatment landscape for…

Editor’s Note: Triple-negative breast cancer (TNBC), characterized by its distinct biology and limited treatment targets, remains one of the most challenging and intensely studied subtypes of breast cancer. At the…

Fifth Bincheng Multidisciplinary Breast Cancer Conference Editor’s Note: The Fifth Bincheng Multidisciplinary Breast Cancer Conference, hosted by the First Affiliated Hospital of Dalian Medical University, was recently held with great…

Hubei Association of Radiation Oncology Physicians 2025 Academic Conference Editor’s Note: The 2025 Annual Academic Conference of the Radiation Oncology Physicians Branch of the Hubei Medical Association was recently held…

The 18th International Conference on Malignant Lymphoma (ICML), organized by the Institute of Oncology Research (IOR), took place from June 17 to 21, 2025, in Lugano, Switzerland. As the most…

At ESMO, Professor Masatoshi Kudo from Kindai University shared results from a matching-adjusted indirect comparison of nivolumab + ipilimumab (CheckMate 9DW) versus durvalumab + tremelimumab (HIMALAYA) and atezolizumab +…

At ESMO, Professor Markus Moehler, Head of the GI Oncology Unit at the University Medical Center Mainz, shared findings from the phase III RATIONAL 305 trial, which evaluated tislelizumab…

Editor’s Note: The 2025 ESMO Gastrointestinal Cancers Congress (ESMO GI), held in Barcelona from July 2–5, brought together leading experts and the latest global advances in GI oncology. Among the…